By: IPP Bureau
Last updated : September 23, 2024 11:07 am
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
AstraZeneca Pharma India Limited will launch Tremelimumab (Imjudo) in October 2024 in India.
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC).
The company received Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Tremelimumab (Imjudo) Concentrate for solution for infusion 20 mg/ml (25 mg/1.25 ml and 300 mg/15 ml presentations in single dose vials) administered through intravenous route on June 1, 2023.